Biocept, Inc. (BIOC)
(Delayed Data from NSDQ)
$0.91 USD
+0.01 (1.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Biocept, Inc. [BIOC]
Reports for Purchase
Showing records 1 - 20 ( 65 total )
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
We are initiating coverage with a BUY rating
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Biocept, Inc.
Industry: Medical Services
1Q18; Lower Than Expected Topline; Adjusting Numbers for Topline Growth Resulting in Changing Our Rating to Neutral Until We See Better Visibility in Adoption
Provider: WESTPARK CAPITAL, INC.
Analyst: CHUNG L
Company: Biocept, Inc.
Industry: Medical Services
4Q17; Slower Than Expected Topline Growth; Adjusting Numbers for Topline and Dilution Resulting in Lower PT to $1
Provider: WESTPARK CAPITAL, INC.
Analyst: CHUNG L
Company: Biocept, Inc.
Industry: Medical Services
3Q17; Natural disaster and fewer sales days impact lighter than expected topline; Adjusting numbers for remainder of 2017; Pathology Partnership Gaining Traction; Overall Outlook intact
Provider: WESTPARK CAPITAL, INC.
Analyst: CHUNG L
Company: Biocept, Inc.
Industry: Medical Services
Healthcare - Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: Biocept, Inc.
Industry: Medical Services
We are placing shares of BIOC Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Biocept, Inc.
Industry: Medical Services
Biocept Launches Molecular Pathology Partnership Initiative as Planned
Provider: WESTPARK CAPITAL, INC.
Analyst: CHUNG L
Company: Biocept, Inc.
Industry: Medical Services
New Marketing Agreement Could Ramp Sales Without Material Impact for Cash Burn
Provider: WESTPARK CAPITAL, INC.
Analyst: CHUNG L
Company: Biocept, Inc.
Industry: Medical Services
Biocept Launches a New Biomarker NRAS to Its Liquid Biopsy Test
Provider: WESTPARK CAPITAL, INC.
Analyst: CHUNG L
Company: Biocept, Inc.
Industry: Medical Services
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
2Q17 Results; Sales force expansion results in incremental volume increase
Provider: WESTPARK CAPITAL, INC.
Analyst: CHUNG L
Company: Biocept, Inc.
Industry: Medical Services
Initiate with a Buy and PT $3.00
Provider: WESTPARK CAPITAL, INC.
Company: Biocept, Inc.
Industry: Medical Services
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Biocept, Inc.
Industry: Medical Services
Company: Biocept, Inc.
Industry: Medical Services
Discontinuation of Research Coverage
Provider: Feltl & Company
Company: Biocept, Inc.
Industry: Medical Services
Q4 roughly inline, large national GPO signed, raise target to $3.00, reiterate BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Biocept, Inc.
Industry: Medical Services
Q4 roughly inline, large national GPO signed, raise target to $3.00, reiterate BUY
Provider: Feltl & Company
Analyst: HAYNOR B